A Phase 2 interventional study of Pioglitazone and Pioglitazone and ramipril in Inflammation and Hypertension, sponsored by Takeda. Completed at 13 sites in Germany. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-07-05.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypertension by Takeda — none open to participants now, none under way, none of them phase 3. Hypertension · Takeda.
Among the 44 studies in Hypertension by Takeda, this one is the 21st largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2007, is one of 4 in phase 2, and was the 13th registered.
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →None of the 44 studies in Hypertension by Takeda is open now. The open studies under Hypertension, anywhere →
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 30 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 26 · Phase 4 2
First in 2004; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 172 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 383 across the 34 interventional studies, 2,647 across the 10 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Hypertension by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on low grade inflammation and vascular function in hypertensive patients.
Patients with insulin resistance and an activated inflammation are prone for cardiovascular complications like myocardial infarction or stroke. Pharmacological interventions reducing vascular inflammation are thought to reduce cardiovascular risk in diabetic and in non-diabetic patients.
Intervention with ACE inhibitors like ramipril is an established and widely used treatment for patients with high blood pressure, proven to reduce cardiovascular risk. Treatment of non-diabetic patients with pioglitazone has shown to improve the cardiovascular risk profile in non-diabetic patients beyond its effect on blood glucose levels.
The purpose of this study is to evaluate effects on low grade inflammation and vascular function of pioglitazone in non-diabetic, hypertensive patients with pre treatment with angiotensin converting enzyme inhibitors (that will be replaced by the study medication at time of randomization).
6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.
This study's enrollment of 172 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Browse Hypertension studies →Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammation. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pioglitazone
Drug: Pioglitazone and ramipril
Drug: Ramipril
Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to: Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks.
Also known as: ACTOS®, AD4833
Drug pages: Pioglitazone · Ramipril
Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to: Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.
Also known as: ACTOS®, AD4833
Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to: Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks.
Change in the high-sensitivity C-reactive Protein value.
Time frame: Week: 12.
Change from Baseline in Glucose tolerance as assessed by an oral glucose tolerance test.
Time frame: Week: 12.
Change from Baseline in Insulin sensitivity according to the Homeostatic Model Assessment - Sensitivity score and Insulin Secretion.
Time frame: Weeks: 6 and 12.
Change from Baseline in Glycosylated Hemoglobin levels.
Time frame: Week: 12.
Change from Baseline in C-Peptide levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Proinsulin intact levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in 24 hours Blood Pressure Profile.
Time frame: Week: 12.
Change from Baseline in high-sensitivity C-reactive Protein levels.
Time frame: Weeks: 6 and 10.
Change from Baseline in Adiponectin levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Monocyte Chemoattractant Protein-1 levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Matrix metalloproteinase-9 levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in P-selectin levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Plasminogen Activator Inhibitor-1 levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Relaxin levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Endothelin 1-21 levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Nitrotyrosine levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Asymmetric Dimethylarginine levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Myeloperoxidase levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in levels of Oxidative Stress as assessed by Per-Ox-Assay.
Time frame: Weeks: 6 and 12.
Change from Baseline in Total Cholesterol levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Triglycerides levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in High Density Lipoprotein levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Low Density Lipoprotein levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Oxidized Low Density Lipoprotein levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Soluble Intercellular Adhesion Molecule levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Soluble Vascular Cell Adhesion Molecule levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Osteoprotegrin levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in 11-dihydroxy-thromboxan B2 levels.
Time frame: Weeks: 6 and 12.
Change from Baseline in Placental Growth Factor levels.
Time frame: Weeks: 6 and 12.
The record gives a start of Mar 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pioglitazone